Zepbound muscle loss is a documented clinical outcome — and so is Ozempic's. Both medications cause lean mass loss alongside fat loss, but emerging evidence suggests tirzepatide (Zepbound) may preserve lean body mass slightly better than semaglutide (Ozempic). Neither drug is free of this effect, and both require a provider-issued prescription. TelosRX connects you with a licensed clinician through an asynchronous evaluation to discuss which compounded GLP-1 option fits your goals.
If you've started a GLP-1 medication and noticed changes in how your clothes fit differently than you expected — less fat but also less muscle tone — you're not imagining it. The scale drops, but the composition of that loss matters for long-term health.
Both Zepbound (tirzepatide) and Ozempic (semaglutide) are effective, evidence-backed weight management tools. The key question for long-term health isn't just how much you lose. It's what you're losing.
Zepbound Muscle Loss vs. Ozempic: How the Mechanisms Differ
Zepbound and Ozempic belong to the same class of medications but work through different mechanisms.
- Ozempic (semaglutide) is a GLP-1 receptor agonist. It activates one receptor pathway to slow digestion, reduce appetite, and promote weight loss.
- Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist. It activates two pathways simultaneously — GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) — producing greater overall weight loss in clinical trials.
This dual mechanism gives tirzepatide an edge in total weight reduction. Trials have shown average losses approaching 20–25% of body weight, compared to 15–20% for semaglutide. But more total weight loss also means more opportunity for muscle loss if protein intake and activity aren't actively managed.
Zepbound vs Ozempic: Head-to-Head Muscle Loss Comparison
| Dimension | Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GLP-1 + GIP agonist | GLP-1 receptor agonist only |
| Lean mass % of total weight lost | ~25% (SURMOUNT-1 DXA substudy) | ~30–40% (STEP 1 and STEP 2 trials) |
| Muscle quality effect | Reduced muscle fat infiltration (SURPASS-3 MRI) | Limited muscle quality data available |
| Total average weight loss (trials) | 20–25% of body weight | 15–20% of body weight |
| Protein co-strategy recommended | Yes — essential | Yes — essential |
| Resistance training recommended | Yes — critical for lean mass | Yes — critical for lean mass |
| Compounded version available | Yes (tirzepatide) | Yes (semaglutide) |
| FDA status (compounded) | Not FDA-approved | Not FDA-approved |
What the Clinical Trials Actually Found About Zepbound Muscle Loss
The clearest data on Zepbound muscle loss comes from the SURMOUNT-1 trial's body composition substudy. Using dual-energy X-ray absorptiometry (DXA), researchers found that approximately 75% of weight lost on tirzepatide came from fat mass, with 25% from lean mass. That's meaningfully better than semaglutide's profile in the STEP trials.
A separate analysis from the SURPASS-3 MRI substudy went further, measuring muscle fat infiltration — a marker of muscle quality, not just quantity. Tirzepatide reduced muscle fat infiltration across all doses, suggesting it may actually improve muscle composition while the person loses fat. A 2025 systematic review in Cureus summarized this evidence, concluding that tirzepatide promotes fat reduction while preserving a relatively stable proportion of lean mass.
The mechanism is still being studied. The GIP receptor pathway may play a role in muscle energy metabolism that semaglutide's single-agonist approach doesn't replicate.
What the Research Shows About Ozempic and Semaglutide Muscle Loss
Semaglutide's muscle loss data comes from the large STEP trials. In STEP 1 and STEP 2, researchers measured body composition changes alongside total weight loss. Across multiple analyses, approximately 30–40% of total weight lost came from lean mass rather than fat. A 2024 review in Diabetes, Obesity and Metabolism confirmed this pattern is consistent across GLP-1–based therapies and called lean mass preservation "a critical consideration."
This doesn't mean Ozempic is unsafe — it means the muscle loss is predictable and manageable. The key variable isn't the drug itself. It's what you do alongside it.
Considering a compounded GLP-1 option? Start a private evaluation at TelosRX — subject to medical approval by a licensed provider.
The Real Differentiator: What You Do Alongside the Medication
Clinical researchers studying both drugs reached the same conclusion: switching from one GLP-1 to another doesn't solve muscle loss. The differentiator is the support strategy.
Three evidence-based approaches make the most difference:
- Protein intake — Research shows GLP-1 users frequently under-consume protein because of reduced appetite. Aim for at least 1.2–1.6 grams per kilogram of body weight daily to support lean mass.
- Resistance training — Strength training 2–3 times per week is the single most effective intervention for preserving skeletal muscle during caloric restriction.
- Dose titration — A licensed provider can guide dose adjustments that balance weight loss pace with muscle preservation goals.
These strategies apply whether you're on tirzepatide or semaglutide. Neither drug alone protects muscle. The medication sets the conditions; your activity and nutrition determine what you keep.
Which Should You Consider: Zepbound or Ozempic?
This comparison isn't a recommendation — it's context. The right choice depends on your medical history, goals, and what a licensed provider determines is appropriate.
That said, the available evidence suggests:
- If total weight loss is the primary goal and you'll actively pair medication with protein and resistance training, tirzepatide's better lean mass profile may be an advantage.
- If you've tolerated semaglutide well and have specific reasons to continue, the muscle loss difference — while real — is manageable with the right lifestyle co-interventions.
- Neither brand-name drug nor its compounded equivalent is FDA-approved for the same indication. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are prepared under federal compounding regulations.
A provider evaluation — not a comparison article — is the starting point. See also: our guide to preserving lean mass on GLP-1 therapy.
GLP-1 Side Effects and Muscle Loss: What's Connected
Muscle loss on GLP-1 medications isn't a side effect in the traditional sense — it's a predictable outcome of caloric restriction combined with reduced protein intake. Managing GLP-1 side effects like nausea and reduced appetite directly influences how much protein you can consume, which in turn affects lean mass retention.
If nausea is causing you to skip meals or avoid protein sources, address that with your provider. Antiemetic strategies, meal timing adjustments, and dose changes all affect the downstream muscle preservation picture.
Frequently Asked Questions
Does Zepbound cause muscle loss?
Yes, Zepbound (tirzepatide) causes some lean mass loss as part of overall weight reduction. However, the SURMOUNT-1 substudy found approximately 25% of total weight lost came from lean mass — a lower proportion than reported with semaglutide. Resistance training and adequate protein intake are recommended alongside any GLP-1 medication. These medications are not FDA-approved in compounded form.
Does Ozempic cause more muscle loss than Zepbound?
STEP trial data for semaglutide (Ozempic/Wegovy) shows 30–40% of weight loss may come from lean mass. SURMOUNT-1 data for tirzepatide (Zepbound) shows approximately 25%. This suggests tirzepatide may preserve a slightly greater proportion of lean mass, though both require active lifestyle co-interventions and are subject to medical approval by a licensed provider.
How much muscle do you lose on semaglutide?
In clinical trials, people using semaglutide lost approximately 30–40% of their total weight loss from lean mass. At a 15–20% total body weight reduction, that could represent meaningful absolute muscle loss — particularly in the legs and arms. High protein intake and strength training significantly offset this.
Which GLP-1 medication is best for muscle preservation?
Current evidence favors tirzepatide over semaglutide for lean mass preservation, based on SURMOUNT-1 and SURPASS-3 data. However, both medications carry muscle loss risk, and no GLP-1 medication is recommended without provider oversight. The choice should be made with a licensed clinician based on your individual health profile.
Does resistance training prevent muscle loss on GLP-1 medications?
Studies consistently show that resistance training reduces lean mass loss during GLP-1 treatment. No published trial has shown complete prevention, but structured strength training 2–3 times per week combined with adequate protein intake significantly improves body composition outcomes compared to medication alone.
Can I get compounded tirzepatide or semaglutide for muscle preservation?
Compounded tirzepatide and semaglutide are not FDA-approved and are available only subject to medical approval by a licensed provider through a legitimate compounding pharmacy. TelosRX offers an asynchronous telehealth evaluation — start at telosrx.com. Individual results vary; approval is not guaranteed.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.